Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.89 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.89 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.89 |
| ▸ | TSHR | P16473 | 4/20 | 0.78 |
| ▸ | USP2 | O75604 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24210195 | 0.91 | KMT2A (0.73) | KMT2ANPSR1KDM4ETSHRUSP2 | |
| SCHEMBL24210095 | 0.83 | TSHR (0.85) | KMT2ANPSR1KDM4ETSHRUSP2 | |
| SCHEMBL24209696 | 0.80 | NPSR1 (0.67) | KMT2ANPSR1KDM4ETSHRUSP2 | |
| SCHEMBL24209876 | 0.80 | KMT2A (0.83) | KMT2ANPSR1KDM4ETSHRUSP2 | |
| SCHEMBL24210088 | 0.78 | KMT2A (0.83) | KMT2ANPSR1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL24019811 | 0.78 | HPGD (0.76) | KMT2ANPSR1KDM4ETSHRUSP2 | |
| SCHEMBL6280222 | 0.78 | ALDH1A1 (0.74) | KMT2ANPSR1KDM4ETSHRUSP2 | |
| SCHEMBL6274361 | 0.76 | ALDH1A1 (0.70) | KMT2ANPSR1KDM4ETSHRUSP2 | |
| SCHEMBL24209779 | 0.76 | KMT2A (0.76) | KMT2ANPSR1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL24209692 | 0.76 | LMNA (0.83) | KMT2ANPSR1KDM4ETSHRUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160067257-A1 | SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY | THE WISTAR INSTITUTE (US) | 2016-03-10 | — | — | US | disclosed |
| US-9234230-B2 | Screening method and compounds for modulating telomerase activity | THE WISTAR INSTITUTE (US) | 2016-01-12 | — | — | US | disclosed |
| US-8377992-B2 | TRBD-binding effectors and methods for using the same to modulate telomerase activity | THE WISTAR INSTITUTE (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120309759-A1 | Screening Method and Compounds for Modulating Telomerase Activity | THE WISTAR INSTITUTE (US) | 2012-12-06 | — | — | US | disclosed |
| US-20100160260-A1 | TRBD-Binding Effectors and Methods for Using the Same to Modulate Telomerase Activity | THE WISTAR INSTITUTE | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309759-A1 | Screening Method and Compounds for Modulating Telomerase Activity | TERT, TERB1, TERF2 | KMT2A 2921/4885NPSR1 4775/4885KDM4E 2189/4885 |
| US-20160067257-A1 | SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY | TERT, TERB1, TERF2 | KMT2A 2921/4885NPSR1 4775/4885KDM4E 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.